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ABSTRACT framykoid peptide (AP) is the major protein component of senile plaques and cerebrovascular amyoid deposis
in Alzheimer's patents. Several researchers have demonstrated that A, is neurotoxic in in vitro and in vivo systems. Peptide
aggregation state and/or conformation might play a signifiant role in determnining the toxicity of the peptde. The size and
flexibility of fibuils formed from the synthetic peptide 18(1-39), coresponding to the first 39 residues of A13, were determined.
Samples were prepared either directly from lyohilized peptide or diluted from a 10 mg/mI stock solution in 0.1°% trifluoroacetic
acid (TFA). All samples had a final peptide conentration of 0.5 mg/mI, a final pH of 7.4, and a final NaCl concentration of 0.14
M. The molecular weight and linear density of the fibrils increased with increasing pre-incubation time in TFA, based on static
light scattering measurdeents. Analyss of angular dependence of the intensity of scattered light indicated that fibrils
were semi-flexible chains and that the fibril flexibility decreased with increasing pre-incubabon time in TFA. There was a
concomitant change in phase behavior from precipitation to gelation with the decrease in fibril flexbility.
INTRODUC I ON
,3-amyloid peptide (A8) is the major protein component of
senile plaques and cerebrovascular amyloid deposits from
Alzheimer's patients (Glenner and Wong, 1984; Wong et al.,
1985; Masters et al., 1985). A,3 is a proteolytic product of a
membrane-associated precursor protein and contains both
extracellular and transmembrane residues of the precursor
(Kang et al., 1987; Haass and Selkoe, 1993). The naturally
occurring peptide has 39-43 residues and displays both N-
and C-terminal heterogeneity (Masters et al., 1985; Prelli
et al., 1988).
Deposition of A,3 in the form of amyloid fibrils is a de-
fining characteristic of Alzheimer's disease. Soluble forms
of A,3 are secreted by some cultured cells and have been
detected in cerebrospinal fluid and in plasma (Haass et al.,
1992; Seubert et al., 1992; Shoji et al., 1992). A43 might play
a significant role in the onset and/or progression of the dis-
ease (Joachim and Selkoe, 1992; Rosenberg, 1993). A num-
ber of experiments have shown that the peptide can exert
considerable neurotrophic and/or neurotoxic effects in vitro
(e.g., Whitson et al., 1989; Yankner et al., 1990; Busciglio
et al., 1993; Loo et al., 1993). In some cases, A,3 was not
directly toxic, but rather increased the susceptibility of the
cells to injury from glutamate (Koh et al., 1990; Mattson
et al., 1992). Results from in vivo experiments have been
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somewhat contradictory. Some researchers have reported
neurotoxic effects or tissue damage caused by injection of
amyloid cores or synthetic peptides (Frautschy et al., 1991;
Kowall et al., 1991; Emre et al., 1992; Kowall et al., 1992),
whereas other reports show no in vivo toxic effect (Clemens
et al., 1992; Games et al., 1992; Podlisny et al., 1992; Stein-
Behrens et al., 1992).
The extent of aggregation and/or the conformational state
may critically influence the degree of toxicity (Pike et al.,
1991a, b, 1993; Busciglio et al., 1992; Simmons et al., 1994).
Toxicity can depend on the source of the peptide (Busciglio
et al., 1992; May et al., 1992). Thus, proper assessment of
the biological activity ofAJ8 may require detailed knowledge
of the physical properties of the peptide in solution.
Some synthetic peptides homologous to A13 have limited
solubility at physiological pH and ionic strength (Hilbich
et al., 1991; Burdick et al., 1992). This has led a number of
researchers to prepare stock solutions of AJ3 in a variety of
solvents before dilution into cell cultures in their toxicity
assays, sometimes with dramatically different results de-
pending on the solvent used (Mattson et al., 1992; Waite
et al., 1992). However, little is known about the effect of
solvents on the aggregation characteristics of the peptide.
In this report, we investigated the effect of predissolving
the synthetic peptide 6(1-39) in 0.01 M phosphate buffer or
0.1% trifluoroacetic acid (TFA) before preparing solutions at
physiological pH and ionic strength. Changes in chemical
composition, secondary structure, fibril structure, and fibril-
fibril aggregation were probed using mass spectroscopy, cir-
cular dichroism, and fluorescence spectroscopy, and dy-
namic and static light scattering. Minor changes in sample
preparation resulted in significant differences in the fibril
size, fibril flexibility, and phase separation behavior. These
changes in fibril characteristics were not accompanied by
measurable changes in chemical composition or secondary
structure.
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MATERIALS AND METHODS
Peptide syntheis and purifition
The peptide (3(1-39) was synthesized and purified by Nuros, Inc. (San
Jose, CA). The peptide sequence, taken from Kang et al. (1987), is
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV. The
peptide was purified by reverse-phase HPLC. Purity was reported as
greater than 95%.
Circular dichroism spectroscopy
(3(1-39) solutions were prepared in 0.1% TFA (Sigma, St Louis, MO) or
by dilution of a stock solution of 10 mg/ml peptide in 0.1% TFA into 0.01
M potassium phosphate buffer, pH 7.6. Fmal peptide concentation was 0.2
mg/mi. The peptide sohlions were filtered through a 0.45 pm Millipore
filter (Bedford, MA) to remove dust and then placed into a vacuum system
to degas. Cirula dichroism spectra in the far-UV (190-240 nm) were
obtained using a modified Cary Model 60 spectropolarimeter (On-line In-
strument Systems, Bogart, GA). A 0.1 cm quartz cell was used for mea-
surements. The instument was calibrated using d(+)-10-camphorsulfonic
acid. The spectral measurements were taken approximately 3 h after
sample preparation. Ten scans of the blank were measured and averaged
as a baseline. Ten runs of each spectrum were measured from which the
baseline was subtracted. The secondary structure was calculated from
mean ellipticities using the standard secondary structural parameters
given by Chang et al. (1978).
Fluorescene measuremrent
Fluorescence spectra for ((1-39) were obtained on a Model M-3 Alphascan
(Photon Technology International, South Brunswick, NJ) spectrofluorim-
eter. The concentration of (3(1-39) was 0.5 mg/ml in 0.1% TFA. The sample
was incubated in a 1 x 0.4 cm2 cuvette at a temperature of 25 + 0.10C.
Fluorescence emission spectra from 285 to 500 mm were measured 3 times
and averaged, usin excitation at 275 mm. Data were collected from 5 mm
to 1 day after sample preparation.
Electron microscopy
A drop of the peptide solution was placed on a pioloform-coated 300-mesh
electron microscope copper grid. After bkltting, a drop of 1% ammonum
molybdate was placed on the grid while it was held with fine forceps. The
grid was blotted on filter paper and aLowed to dry before observng the
specimen in a JEOL (Peabody, MA) IOOCX Elecrn Microscope at 60 kV.
High-performance liquid chromatography (HPLC)
HPLC experiments were performed using the Waters (Millipore, Milford,
MA) Model 625 LC system and the Waters Protein-PAK 125 aclumn. The
mobile phase was 0.1% TFA at a flow rate of 1 ml/min. Ten p1 of 10 mg/ml
1(1-39) in O.1% TEA was injected. E hlim peaks were deeed by absolxnce
at 280 mnm The coumn was cabliratd with ovahumin (43 kDa), myoglotin
(17 kDa), rbonudease A (14 kDa), and insulin (5.7 kDa) (all from Sigma)
Matn_ daslatsd btserd ionmionon mass
setscopy (MALDI)
MALDI mass spectmetry was performed using a Vestec Model VT 2000
(Houston, TX) laser desption linear (2 m) time-of-flight mas specom-
eter modified with a 24 sample loading system combined with video camera
vwing, Desorpionioiation of the sample was accomplished with a Lu-
monics (Warwickshire, England) Model HY 400 ND:YAG laser frequency
tripled to 355 nm The laser pulse width was 10 ns, and the pulse frequncy
was 10 Hz. Ions were accelerated in one stage thuough a potential of 30 keV
the source region and detected by a 20 stage focused mesh electron
multiplier (Becton-Dickinson Model MM1-1SG) at the end of the flight
tube. A particle guide made of nickel wire (0.12 mm in diameter) also
spanned the length of the 2 m flight path, and was biased at 120 V so ions
were efficiently tansported along the center axis of the flight tube. All
spectra were obtained using the matrix alpha-cyano-4-hydroxycannamic
aid (Aldh, Milwaukee, WI) in the positive ion mode and summed over
50 laser shots. Trne to mass conversion was accomplished using insulin
(MW = 5733.5 Da) as an internal standard.
matrix solutions were prepared fresh dafly in 50/50 acetoni-
tile/water. Lyophilized (3(1-39) was dissolved in pure water, 0.1% TFA,
or 0.5% TFA to give an analyte concentration of 10 p.M. Typically, 5 p1
of sabtuatd matrix solution was mixed with 1 of analyte solution and 1 p1
of an aqueous insulin sohiion (10 pM) before deposition of2 p1 of this mixtue
on a stainless steel probe tip. The solvent was allowed to evaporat at room
temperature before inertio into the sounr region of the mass spedumeter.
Static light scattering
All aqueou buffers were double-filtered through a 0.22-p.m filter (Milli-
pore, Bedford, MA) before use. All samples had a final peptide oncen-
traion of 0.5 mg/mI, a final pH of 7.4, and a final salt concentration of 0.01
M KI,HPO,/KH2PO4 and 0.14 M NaCL A summary of the sample prepa-
ration methods is shown in Table 1. Sample A was made by dissolving
0.5 mg of lyophilized peptide into 05 ml of 0.01 M phosphate buffer con-
tamining 0.02% (w/v) sodium azide, then diluting with 0.5 ml of 0.01 M
phosphate buffer, 0.28 M NaCl, and 0.02% (w/v) sodium azide. The pH was
adusted to 7.4 with 0.5 N NaOH. Samples B, C, and D were prepared from
stock solutions of (3(1-39) at 10 mg/ml in 0.1% TFA that were allowed to
stand at room temperature for 5 min, 1 h, and day, respectively, and then
diluted into phosphate buffered saline (PBSA.- 0.01 M K2HPO./KH2PO4,
0.14 M NaCI, 0.02% (wtv) sodium azide) to a final concentration of 0.5
mg/mi and a final pH of 7.4. Sample E was prepared to exchlde any pos-
sibility of oxidation. (3(1-39) at 10 mg/ml was made by dissolving 0.5 mg
of lyophilized peptide in the presence of 0.5 mg of dithithreitol (DIT,
Sigma) in 50 p11 of 0.1% oxygen-free TFA, which was sparged with helium
at a flow rate of 100 ml/min for 1 h before use. The sample was stored in
a 1.5 ml Ependorff tube that had been sparged with nitrogen, sealed by
parafilm, and incubated for 1 day at 25°C. The stock solution was then
diluted into PBSA to give a final peptide concentration of 0.5 mg/mi at pH
7.4. All samples were filtered with a 0.45-pm filter (Millipore) and trans-
ferred into a pre-cleaned 8mm o.d. cylindrical light scattering cell (Hellma,
Jamaica, NY). The concentration of some samples was checked using a
Hitachi Model U-2000 UV-VIs specrophotometer (Hitachi, Chigo, IL)
before and after filtation; there was no significant klss in absorbance at 280
nm due to filtration.
TABLE 1 Sumnary of sanple prepaation method
Preincubation time
Sample Initial stock solution in stock solution Fimal solution
A 1 mg/ml (3(1-39) in 0.01 M phosphate 1 min 0.5 mg/ml (3(1-39) in PBSA
B 10 mg/mi (3(1-39) in 0.1% TFA 5 mi Same as Sample A
C Same as Sample B l h Same as Sample A
D Same as Sample B 1 day Same as Sample A
E 10 mg/ml (1-39) in He-sparged 0.1% TFA with 10 mg/ml DTT 1 day Same as Sample A
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Static li (SLS) expin wr perfonmed a
Malvern 4700c paricle analyzer with a 128-chansel autoconelator
(Malver, Soutxib gh, MA) and a Lexel Model 95-2 argon-ion laser
(Lexel Laser 1nc, Fremont, CA) equipped with an etaln. The laser was
operatedatapowerof 75-200mW and ata wavelngth of488 nm The laser
beam was focused coto the scatring celL The entire assembly was klveled
and fixed onan optical tabk (Technical Manufacring Co-, Brockton, MA).
The scattering cell was placed in a temperature-controlled bath con-
taining the refractive index matching fluid decahydronaphthalene (Al-
drich, Milwaukee, WI), which has a refractive index of 1.479. T'he
temperature was controlled to 25 ± 0.1 °C using a circulating water bath
(VWR, Chicago, IL). To reduce stray light, the equipment was enclosed
in a black box.
The scattred light intensity I,(9) was coUlected for 12 s at 22 different
angles between 20" and 140". Each srmt was repeated 10 times and
then averaged. The scattred light insy of the x nd d solvent
c ri- Ib() was dtn nmeasd at the se co f ins- The resuks re
tina d wiih rsea to immensity data I,() from grale
tkem (Akkich) t o nthe Raylgh ratio Rk(q).
For nacroieculs, static light data are commonly repe-
sented by
Kc 1
R.(q) P(qXM) B (1)
The moments (r2) and (r5 are given as (Benoit and Doty, 1953)
(rz) = 42X _42 O1 - e-x)
2 2
(4)= A44 12X2-9x -54 -e-h) + 2(l - e 2x
where x = 2dlk.
(6)
The mean square radius ofg (R.') of a semi-flexible chain can be
evaluated from (Benoit and Doty, 1953)
27LC= 42 43 4((RS2 6 4 L _ 2 (1 e(-2LSb), (7
The scanered intensity data were plotted as KdR,(q) vs. q2 and fit by
weighted least-square regression to a staight line at the low angles. From
the slope and ine, (R2) and (MP.,,, were determined along with
SDs. Light scattering data were plotted as q2P(q) vs. q or as qP(q)Ii
vs. q(RP (Schmidt et al., 1985). These formats are known as Kratky
and Holtzer pklts, respectively. Eqs. 4-6 were fit by inspection to the
Kratky and Holtzer plots to determine L, and l,.
Dynami light scattering
where c is the concentation of sample (g/ml). (M)1 is the weight-averaged
moeculr weight of the particles in sohlton P(q) is a particle scattering
factor, K = 4NdIW dC)2NALA4 WdIdc is the refratve index inem NA
is Avogadro's number, A is the wavelength of the light in vacuo, and B is
the second virial coefficienL For determinaion of dW/dc, solutions of
peptide were made at known concentrations and the refractive index of
the solution was measured using a Milton-Roy (Rochester, NY)
Abbe-3L refractometer. The refractive index increment was determined
to be 0.112 ml/g.
For our systm, K was assumed to be inde of the state of ag-
gregon. At low concenttons and low angles (low q), Eq. 1 can be
rewriten as
Kc I( ,~
R,(q) (M),,3,A'+)' (2)
where q is the scring vector (=4wnA0sin(/2)), (M),,.. is the apprn
weight-averaged moecula weight, and (RP, is the light-sat g-
averaged squared radius of gyraion.
For partcles with dime similar to the wavelength of the incident
light, the angular dependence of the scattered intensity can be used to
obtain informaon on the shape of the particles in solution. The scat-
tering factorP(q) can be evaluated from the intensity data over the entire
range of q from
Dynamic light scatering (DLS) expeiiments were conducted using the same
apparatus and samples as used for SLS experiments The scatered light
intensity was coLected at 900 from the tansmittd beam and converted to
the wnalzed first-order electric field autocorrelation fuci g"'1(T),
where Tis the decay time. Data were coflected for 20 nis for 30 s duration
each time and then averaged. Data were analyzed using the nmetdod of cu-
,lants, by fitting to the third-ord cumulans expression
nIn lg4"') I =- + 2! 3! (8)
where (I) is the initial decay rate, and p., and IL3 are the second and third
moments, respectively. (I)-' can be considered a relaxaion tine, corre-
sponding to the time scale for motion of the particles in solution. (F) is
related to the apparent z-average translational diffusion coefficient by
(() (9)
where the particle shape factor, internal motions, and intemoleculr inter-
actons are not accoted for. An apparent hydrodynamic radius (Rb),p can
be lased frm the Stokes-Esein equaion
(R)= 6k8T(D),.. (10)
1 (q) R(qA) - (3)
Tbe theoretical scattering factor P(q) for semi-flexible chains is given
by (Koyama, 1973)
P(q) = (L -t eV( it - tf(t)) x dt, (4)42(Lc t)- -qq-:gQ
where Lc is the contu kngth and lk is the Kuhn statisfical segment length,
which is equal to 2 times the persistence length L. The ftuncions tf(t) and
tg(t) are
f(t) )( 2g()
(5)
2g(tf)= ( (- I -)) K= (yr4)K( )2'
where k, is the Boltmann constan T is the absolute tmperatue, and it
is the solvent viscosity.
For semi-flexible chains, the hydrodynamic radius R1 can be calculated
USiequaons derived by Yamakawaand Fuii (1973). For chains that have
Lclk > 2278, the hydrodynamic radius is given as
--Al- +A,+AI-l +A4-l+5-
2 Rb (ik ) Ii ) k ) I
For LAlk '- 2-278,
- c, In(d) + C, + C3 () + C4() + (
(1 1)
(12)
+ C6 ()In ) + C7() + Ca() C9 -()+ CI f-
where d is the hydrodynamic diameter of the chain, and the coefficiets Ai
and C' are given by Yamakawa and Fujii (1973).
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FIGURE 1 Mass spectra for (A)
18(1-39) in water for 20 min, (B) (1-39)
in 05% TFA for 20 mm, (C) 3(1-39) in
05% TWA for 24 h, and (D) ^1-39) in
05% TFA with 0.8M2M
for 24 h.
3800 4000 4200 4400 4600
M/Z
RESULTS
Oxidization of 3(1-39) in TFA
MALDI sWectra for 1(1-39) in both pure water and 05%
TFA were taken immediately after sample preparation; re-
sults are shown in Fig. 1, A and B, respectively. Intense sig-
nals at MIZ = 4233.0 (Fig. 1 A) and 4231.7 (Fig. 1 B) were
observed, consistent with the calculated molecular mass of
4232 for monomeric 1(1-39). Virtually identical spectra
were obtained for 13(1-39) in 0.1% TFA immediately after
sample preparatIo and for 13(1-39) in 0.1% TFA 24 h after
sample prearation (data not shown). The spectrum for
13(1-39) in 0.5% TFA for 24 h after sample preparation is
shown in Fig. 1 C. An intense signal for the singly charged
peptide at the appropiate molecular mass was observed. In
addition, a significant high molecular mass shoulder at M/Z
-4247.1wasdetected.Thesample in Fig. 1 Cwasteated
with 0.8 M 2-mercaptoethanol for 48 h, and a spectrum was
obtned (Fig. 1 D). The high molecular mass shoulder dis-
appeared, although the peak width was greater than in Fig.
1 B. Based on these results, no degradation or change in
chemical composition occurs after one day in 0.1% TEA or
water. The data suggest that the peptide is partially oxidized
after 24 h in 0.5% TFA, preumably at Met-35.
Seondar struwctre
Circular dichroism spectra are shown in Fig. 2. Two samples
were prepared by dilution of a stock peptide solution in 0.1%
TFA into phosphate buffer. The samples were incubated for
different lengths of time in TFA before dilution. For both
samples, analysis of the spectra iict a content of ap-
proximately two-thirds 1-sheet and one-third random coil.
This result was independent of the time period of incubation
of 1(1-39) in 0.1% TEA. The sectrum of the peptide in
0.1% TFAwas considerably different than that ofthe pptide
in phosphate buffer. In 0.1% TFA, 13(1-39) contained ap-
proximately one-third 1-sheet, one-fourth -turn, with the
remainder random coil.
ITe fluorescence emission sectrum of 13(1-39) in 0.1%
TFA was measred with excitation at 275 nm. An emission
maximum was observed at 302 mm (data not shown), which
is characteristic of tyrosine emision (Jordano et aL, 1983).
Fluorescence emission was followed for 5 min to 24 h after
sample preparation. Tyrosine fluorescnce is prtally
E
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FIGURE 2 Cirular dichroism spectra for 1(1-39). 10 mg/ml 1(1-39)
dissolved in 0.1% TFA for 5 min then diluted into 0.01 M phosphe buffer,
pH 7.6 (A), 10 mg/mI P(1-39) dissolved in 0.1% TFA for 3 months ten
diuted into phophate buffer (@), and P(1-39) in 0.1% TFA (0) Fmal
peptide conentratiOn for anl samples was 0.2 mgtmL Spectra were obtained
3 h after sample pr
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quenched when hydrogen bonded with water and totally
quenched when hydrogen bonded with a carbonyl oxygen
(Cowgill, 1976). There was no change in the fluorescence
spectra or in the peak intensity as a function of time (data not
shown). This indicates that there was no measurable change
in the tyrosine residue environment under the experimental
conditions.
Size exclusion HPLC
For 10 mg/ml (3(1-39) in 0.1% TFA, with 0.1% TFA as the
mobile phase, the HPLC chromatogram showed a single
sharp peak. Based on calibration of the column, this corre-
sponded to an apparent molecular mass of approximately 6
kDa (data not shown). No significant change was detected
when the sample was injected one day after preparation.
These results show that the peptide is dissociated, probably
into monomers, in 0.1% TFA.
Confirmation of presence of amyloid fibrils
Peptide solutions prepared either directly by dissolution of
lyophilized peptide into phosphate buffer, or by dissolution
of lyophilized peptide in 0.1% TFA followed by dilution into
PBSA both showed a red shift in the absorbance spectra of
Congo red (data not shown), characteristic of amyloid fibrils
(Klunk et al., 1989). Electron micrographs showed that the
peptide formed fibrillar structures with an apparent diameter
of approximately 10 nm. Representative micrographs of
Samples B and D, taken several days after sample prepara-
tion, are shown in Fig. 3.
Characterization of fibril size and structure by
light scattering
SamplesA to D were analyzed by static light scattering. The
data were collected 12 h after dilution into PBSA. Intensity
data were plotted as Kc/R,(q) vs. q2 in Fig. 4. Because ag-
gregation is concentration-dependent, experiments at mul-
tiple concentrations could not be performed and analyzed
using a conventional Zimm plot. Equation 2 was used to
analyze the data for values of q2(Rg2)zQp < 4. This limit was
chosen because P(q)-' is fairly independent of particle shape
for values of q2(R2)z,, <4 (Benoit and Doty, 1953).(Rt2)ip was obtained from the slope of the plot at low q to
satisfy the aforementioned limit. (M),pp was calculated from
the intercept of KcIR,(q) vs. q2. Results are shown in Table
2. (M),,p for Samples A and B were not significantly dif-
ferent. In contrast, (M),,pp increased with increasing pre-
incubation time in 0.1% TFA (Samples C and D).
By recasting the data in a different form, structural infor-
mation was obtained (Schmidt et al., 1985). P(q) was cal-
culated from the data using Eq. 3 and the value of (M).,pp
listed in Table 2. Intensity data were replotted as q2P(q) vs.
q in Fig. 5 and as qP(q)Ir vs. q(RzlQ in Fig. 6. These
formats are known as Kratky and Holtzer plots, respctively.
For flexible chains, a definite plateau appears in the Kratky
A
I
FIGURE 3 Electron micrographs of peptide solutions at 24,500X
magnification, taken several days after sample preparation. (A) Sample
B, incubated for 5 min in 0.1% TFA before dilution into PBSA. (B)
Sample D, incubated for 1 day in 0.1% TFA before dilution into PBSA.
Sample preparation is described in more detail in Materials and Methods
and in Table 1.
plot (Fig. 5); the height of the plateau corresponds to 12/Ljk.
For stiff, rodlike chains, no definite plateau emerges. In the
Holtzer plot (Fig. 6), the asymptotic value at large q
(Rg2) corresponds to 1/Lc. A maximum appears at inter-
mediate values of q(Rg) 2 for chains with some flexibility,
whereas for rods there is no internal maximum. The ratio of
the maximum to the asymptotic value (at large q) of qP(q)/h
is proportional to the number of segments Nk, where Nk =
L/4. The stiffer the chain, the lower the value of Nk. The
position of the maximum indicates the degree of polydis-
persity, U, which is a measure of (MwX(M),n where (M)n iS
the number-averaged molecular weight
Theoretical curves for P(q) as a function of L4 and 4 were
generated from Eqs. 4-6 and compared with the experimen-
tal data. The best fit determination of Lc and 4 was made by
visual inspection. The calculated curves for P(q) are shown
along with the data in Figs. 5 and 6. The chosen fit to the
experimental data is shown as a solid line in Figs. 5 and 6,
and the chosen values of Lc and 4 are included in Table 3.
In Figs. 5 and 6, most of the experimental data were included
in the region between the two dotted curves that were com-
puted using Lc ± 100 am and 4k + 10 nm for Samples A, B,
and C, and Lc 50 mm and k -+ 10nm for Sample D. The
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FIGURE 4 KcIR5(q) vs q2 for 0.5 mg/ml 13(1-39) in PBSA, pH 7.4.
Sample A was made dedly from lyophlizd peptide. Samples B, C, and
D were madefm 10 mg/ml (1-39) that was iu;bated in 0.1% TFA for
5 min, 1 h, and 1 day, rspectively, before d&tion into PBSA. Sample
prepaation is dcsbed m more detail m Materals and Methods and m
Table 1. Open cires show rimental data. Error bars show the SD for
intensity measuements at ech angle. The data were fit usng the stucture
facor of the flcibk chain (Eqs 4-6, ----). (M),. and (Rp),., were
deterinedh the slope and intrcept of the sod line, which repesents
the fit of the data to Eq. 2.
TABLE 2 Smimy of Si mad DLS resuib
(MswA(Wr£ (Rh,
Sampk (10'Da) (am) (nm)
A 9.6 + 0.4 138 ± 9 100
B 92± 0.6 128 + 10 90
C 14.0+05 128+6 100
D 25.4 ± 4.0 159 + 32 360
theoretical radius ofgyration was calculated from Eq. 7 using
the values ofLc and 1' listed in Table 3. The calculated radius
of gyration was consistent with the experimentally deter-
mined value (Table 2).
In Figs. 5 and 6, for SamplesA to C, a clear plateau in the
Kratky plot and a clear intermediate maximum in the Holtzer
plot were present, indicative ofa semi-flexible chain, In con-
trast, for Sample D, there was no dear plateau in the Kratky
plot and only a very small intermediate maximum in the
Holtzer plot, indicative of a stiffer stue. These qualita-
tive observations are reflected in the values of lk and Nk for
the four samples. Specifically, the Kuhn length 'k is consid-
erably greater, and the number of segments Nk is consider-
ably smaller, for Sample D. The contour length L4 decreased
with increasing pre-incubation time in 0.1% TFA.
An estimate of the degree of polydispersity U, as de-
termined from the location of the maximum of the curves
plotted in Fig. 6, is listed in Table 3. All samples have
similar, relatively narrow polydispersities. The mass lin-
ear density ML was calculated from (M),,,,PIL,. In addi-
tion, the apparent diameter d,pp was calculated using the
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FIGURE 5 Kratky plots for Samples A, B, C, and D. Open circles show
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FIGURE 6 Hohzer plots for Samples A, B, C, and D. The same symbols
are used as in Fig 5.
estimated hydrated specific volume Vi of 8(1-39) of 1.11
cm3/g (Kuntz and Kauzmann, 1974; Cohn and Edsall,
1943) and the equation
= 4 ML. V,)0-
APPV NAJ (13)
For SamplesA and B, d,, is virtually the same. However,
Sample D had a higher d,p than SamplesA and B; Sample
C had an intermediate dP_
DMS measurements were taken on these samples, begin-
ng 20 min after sample preparation and continuing for sev-
eral days. The decay rate (F) at 90° vs. time for the fist 48
h is plotted in Fig. 7. The initial value of (F) increased with
increasing pre-incubation time in 0.1% TFA. However, the
value of (I) at 48 h decased with increasing pre-incubation
time. There was a slight drop in (I) of Sample A over time.
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TABLE 3 Suwm ary of calulato result from Eqs 4-7 and 11-12
LC 1* M/LC dp (Rg-)V Ru
Sample (nm) (nm) (103 Da/nm) (nm) Nk U (nm) (nm)
A 1400 90 7 4 16 1.5 138 75
B 1400 85 7 4 16 1.4 135 74
C 1100 90 13 6 12 15 121 67
D 750 300 34 9 2.5 1.4 149 70
4
-
L-
3
2
1
0 10 20 30
Time (hr)
40 50
FIGURE 7 (f) vs. time for Samples A (0) B (0), C (A) and D (A).
In contrast, (F) of Sample B decreased gently from 1850 to
1180 s-'. (F) of Sample C dropped evenly from 2200 s-'
to 400 s- . (F) of Sample D decreased rapidly from 3580 to
500 s-' at the first 10 h, then was about constant at 400 s- .
The plot of (r) against t for Sample E was similar to Sample
D (data not shown).
(R,,p was calculated from (F) for the data taken at 12 h
after sample preparation using Eqs. 9-10. Results are shown
in Table 2. The theoretical hydrodynamic radius was calcu-
lated from Eqs. 11 and 12 using the values of L4, k, and dp
from Table 3 and compared with the experimental data. Re-
sults are included in Table 3. In all cases, the theoretical value
of R,, was smaller than the experimentally determined value;
the discrepancy was greatest for Sample D.
An attempt was made to obtain SLS and DLS data on
(3(1-39) in 0.1% TFWA Scattered intensity was extremely
weak, indicative of the substantially smaller size of the pep-
tide in this solvent relative to that in PBSA. The particle size
was still not measurable 1 week after sample peparation,
indicating that no significant aggregation occurred in this
solvent over time.
Phase separation
Ihe onset of phase changes was determined by holding the
light scattering cuvette to a light source and examining the
sample by eye, and by gently tipping the cuvette to observe
any flow. The time for visible precipitate formation of the
samples depended on the initial stock solution. Sample A
formed visible precipitates after 4 days. Sample B formed
visible precipitates after 7 days. In contrast, no visible pre-
cipitates were observed in Samples C and D after 2 weeks.
However, Samples C and D appeared viscous after 1 week,
as determined by visual inspection. After a period of several
weeks, a small amount of precipitate was eventually evident
in Samples C and D.
DISCUSSION
Determination of the aggregation characteristics ofA(3 might
be important in understanding its physiological role. In work
reported here, we used light scattering to obtain size and
structural information of the fibril in solution. Preparation of
samples from 0.1% TFA stock solutions was chosen for two
reasons: (1) the low pH can potentially disaggregate any
pre-aggregated material in the lyophflized peptide, hence
leading to starting conditions that contain only monomeric
peptide, and (2) 0.1% TFA is commonly used in 35% ace-
tonitrile solutions for peptide purification and in stock so-
lutions used in toxicity studies.
When dissolved in 0.1% TFA, with 0.1% TFA as a mobile
phase, the peptide eluted on a size-exclusion column with
residence time close to that of a monomer. DLS and SLS
experiments confirmed that the peptide was unaggregated
under these conditions. There was no detectable change in
the tyrosine environment over time for the peptide dissolved
in 0.1% TFA, as measured by fluorescence. In this solvent,
our analysis indicated that the peptide contained some
,B-turn. Barrow et al. (1992) reported a greater (72%) fraction
of random coil for (3(1-39) in water buffered with 5 ±LM
potassium phosphate at pH 2.8. The difference is possibly
caused by a difference in the choice of reference spectra and
the inclusion of (3-turn in our analysis.
Upon dilution into phosphate buffer at neutral pH, (3-sheet
content increased concomitant with aggregation of the pep-
tide. The secondary structure characteristics were very simi-
lar to those we reported previously for (3(1-40) (Tomski and
Murphy, 1992) and did not depend on the length of time that
the sample was incubated in 0.1% TFA before dilution. Pre-
dissolving ((1-39) in 0.1% TFA before dilution into PBSA
resulted in an initially smaller size (greater relaxation rate
(F)) as measured by DLS, when compared with dissolving
lyophilized peptide directly into phosphate buffer. The size
of the sample 20 min after preparation decreased with in-
creasing pre-incubation time in 0.1% TFWA However, at only
20 min after sample preparation, (R,),p was 40 to 90 nm,
which is substantially larger than the size expected for mo-
nomeric ((1-39). These results indicate that self-assembly of
(3(1-39) proceeds very rapidly upon introduction of a buffer
at physiological pH and ionic strength.
SLS data taken 12 h after dilution of the peptide into PBSA
provided a "snapshot" picture of the average fibril size and
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architecture. At this time fibrils, with lengths on the order of
1 pim, contained an average of approximately 2000-6000
monomers. With increasing pre-incubation time in 0.1%
TFA, fibrils of greater linear mass density, greater average
molecular weight, and shorter contour length were formed.
The molecular weight of Sample D was roughly 2 to 3 times
that of Sample A, B, or C. The increase in linear density and
corresponding increase in stiffness was largest for Sample D.
These effects might be caused by lateral alignment of fibrils.
Aligned filaments have been commonly reported in electron
micrographs of amyloid fibrils (e.g., Narang, 1980; Merz
et al., 1983; Halverson et al., 1990; Fraser et al., 1991). Tama-
rind seed polysaccharide has been reported to undergo a simi-
lar lateral aggregation process, resulting in an increase in stiff-
ness (Lang et aL, 1993). Alteratively, the changes in linear
density and fibril flexibility might be caused by stuctural
changes in the way that peptide monomers "pack" into fibrils.
The differences among the samples were not caused by
changes in secondary structure or chemical composition, as
described above. One possibility is that there are some stable
preformed aggregates in the lyophilized peptide that are only
slowly lost during incubation in TFA. Longer incubation
times in TFA would lead to an increase in the concentration
of monomers at the expense of these preformed aggregates,
and changes in the average properties of the aggregated
peptide. This hypothesis would be consistent with the
smaller initial size with increasing pre-incubation time in
TFA (Fig. 8).
The theoretical Rh was smaller than that actually measured.
This could be caused by a number of effects. First, the theo-
retical Rh was calculated assuming that the diameter deter-
mined from the linear density corresponded to the hydro-
dynamically effective cross section. However, if the fibrils
are loosely twisted or have frayed ends, the hydrodynamic
cross section would be considerably greater, which would
lead to a larger Rh. Second, effects of polydispersity were
ignored in calculating the theoretical Rh.
Samples C and D remained soluble for several weeks,
forming gels before precipitating. Physical gelation often oc-
curs in stiff rod systems because of kinetic limitations (Tracy
and Pecora, 1992). The increased rigidity of the fibrils, es-
pecially in Sample D, could lead to fibril entanglement and
physical gelation. At 48 h, (F) for Sample C is similar to that
for Sample D; this suggests that at longer times, these fibrils
also aggregate laterally and increase in stiffness. Thus, the
increased rigidity would lead to gelation for this sample. All
samples eventually contained some insoluble material.
In interpreting the results from light scattering, three
points must be addressed. First, in the analysis of SLS data
using Eq. 2, the contribution of the second virial coefficient
B was neglected. Assuming hard-core interactions only, the
theoretical value ofB for a rigid rod was calculated (Goinga
and Pecora, 1991). From this, we estimated that the contri-
bution from this term would lead to an increase in (M)w of
at most -20% for Samples A and B, -10% for Sample C,
and -5% for Sample D. Second, in determining the shape
from the particle structure factor, we assumed that the fibrils
are linear nonbranching chains and that interparticle effects
are negligible. For many branched structures, an internal
maximum in the Kratky plot appears (Burchard and Muller,
1980). This was not seen in our results. Furthermore, the
theoretical and experimental values of radius of gyration
agreed quite well, which would not be true for branched
structures. For Samples A and B, the experimental data lie
just slightly above the theoretical curve at intermediate q on
a Kratky plot (Fig. 5). This could be because ofa small degree
of branching (Kajiwara and Ribeiro, 1974). Overall, how-
ever, the analysis of the fibrils as nonbranching chains ap
pears justifiable. Third, the downward curvature at large q
seen in Fig. 5 D could be caused by an increase in polydis-
persity rather than an increase in stiffness (Franken and Bur-
chard, 1973). This is unlikely given the fact that the poly-
dispersity index U is similar for all four samples.
To summarize, fibril dimensions, flexibility, and solubility
can be altered by small changes in sample preparation
method. Peptide self-assembly occurs very rapidly under our
experimental conditions, and some forms of aggregated A43
can remain soluble for considerable time periods. In assess-
ing the role of aggregation state on the biological activity of
A43, it is important not to assume that peptide solubility cor-
responds to unaggregated peptide; this distinction has not
always been clearly made. Effects ofsample ea o on fibril
characteristics can be int in altering the outcome of tox-
icity assessments of A13 and need to be considered carefully
when analyzing data on the biological actvity of Af3.
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